SUBSCRIBE
SUBSCRIBE

Viking Therapeutics

NEWS
Drug Development
Is NASH Really a $35 Billion Opportunity?
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
September 25, 2018
 · 
4 min read
 · 
Karl Thiel
Drug Development
NASH Race Heats up as Viking Therapeutics Announces Stellar Phase II Data
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
September 18, 2018
 · 
3 min read
 · 
Mark Terry
Gemini Therapeutics Banks $42.5M to Bring Precisio
Bio NC
Top 6 Biotech Stocks of 2017
When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.
December 20, 2017
 · 
1 min read
Load More
JOBS
IN THE PRESS
Drug Development
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
March 28, 2023
 · 
6 min read
Drug Development
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
March 28, 2023
 · 
8 min read
Biotech Beach
Viking Therapeutics to Participate at Upcoming Investor Conferences - March 7, 2023
March 7, 2023
 · 
2 min read
Business
Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
February 8, 2023
 · 
16 min read
Biotech Beach
Viking Therapeutics to Present at SVB Securities Global Biopharma Conference
February 7, 2023
 · 
2 min read
Business
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023
February 1, 2023
 · 
2 min read
Drug Development
Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
January 9, 2023
 · 
6 min read
Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints
January 2, 2023
 · 
2 min read
Biotech Beach
Viking Therapeutics to Present at Stifel 2022 Healthcare Conference
November 8, 2022
 · 
2 min read
Business
Viking Therapeutics to Report Financial Results for Third Quarter 2022 on October 26, 2022
October 19, 2022
 · 
2 min read
Load More